fda import alert glp-1 semaglutide tirzepatide green list 2025 May 4, 2025: New study suggests more adverse events associated with compounded GLP-1s than standard formulations – Partnership for Safe Medicines Compounded Semaglutide & Tirzepatide 2025:

Food and Drug Administration (FDA) about these findings and recommends that people using these untested products contact their physicians for advice and discussion on alternative treatment options. The Study Identified a Chemical Reaction Between Tirzeptide and Vitamin B12 Lillys laboratory testing found that the interaction between tirzepatide and vitamin B12 produced a molecule larger than tirzepatide alone a change that could theoretically affect how the drug is absorbed, distributed, metabolized, or eliminated in the body, the study authors wrote

Clinical trials have shown impressive results based on dosage levels: 5 mg: Average weight loss of 15% body weight

The vendor landscape changes rapidly

Additionally, the study looked at cardiovascular outcomes as a pre-specified secondary analysis which included a four-point composite endpoint of cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina

Are there side effects